United Therapeutics Future Growth
Future criteria checks 1/6
United Therapeutics is forecast to grow earnings and revenue by 6.8% and 6.7% per annum respectively. EPS is expected to grow by 5.6% per annum. Return on equity is forecast to be 12.3% in 3 years.
Key information
6.8%
Earnings growth rate
5.6%
EPS growth rate
| Biotechs earnings growth | 28.0% |
| Revenue growth rate | 6.7% |
| Future return on equity | 12.3% |
| Analyst coverage | Good |
| Last updated | 16 Oct 2024 |
Recent future growth updates
Recent updates
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27
United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,281 | 1,330 | 1,339 | 1,740 | 12 |
| 12/31/2025 | 3,085 | 1,302 | 1,236 | 1,529 | 15 |
| 12/31/2024 | 2,819 | 1,188 | 1,055 | 1,264 | 15 |
| 6/30/2024 | 2,617 | 1,069 | 878 | 1,106 | N/A |
| 3/31/2024 | 2,498 | 1,051 | 752 | 980 | N/A |
| 12/31/2023 | 2,328 | 985 | 748 | 978 | N/A |
| 9/30/2023 | 2,204 | 900 | 764 | 956 | N/A |
| 6/30/2023 | 2,111 | 872 | 674 | 868 | N/A |
| 3/31/2023 | 1,981 | 728 | 722 | 889 | N/A |
| 12/31/2022 | 1,936 | 727 | 664 | 803 | N/A |
| 9/30/2022 | 1,860 | 707 | 679 | 849 | N/A |
| 6/30/2022 | 1,789 | 631 | 652 | 776 | N/A |
| 3/31/2022 | 1,768 | 687 | 673 | 797 | N/A |
| 12/31/2021 | 1,686 | 476 | 477 | 598 | N/A |
| 9/30/2021 | 1,655 | 462 | 487 | 550 | N/A |
| 6/30/2021 | 1,591 | 471 | 560 | 615 | N/A |
| 3/31/2021 | 1,506 | 405 | 574 | 631 | N/A |
| 12/31/2020 | 1,483 | 515 | 696 | 756 | N/A |
| 9/30/2020 | 1,410 | 469 | 660 | 732 | N/A |
| 6/30/2020 | 1,431 | 430 | 597 | 667 | N/A |
| 3/31/2020 | 1,443 | 528 | 564 | 635 | N/A |
| 12/31/2019 | 1,449 | -104 | -290 | -207 | N/A |
| 9/30/2019 | 1,519 | -92 | -334 | -224 | N/A |
| 6/30/2019 | 1,530 | -118 | -310 | -172 | N/A |
| 3/31/2019 | 1,601 | -150 | -297 | -125 | N/A |
| 12/31/2018 | 1,628 | 589 | 594 | 778 | N/A |
| 9/30/2018 | 1,711 | 543 | 447 | 607 | N/A |
| 6/30/2018 | 1,744 | 713 | 487 | 628 | N/A |
| 3/31/2018 | 1,744 | 484 | N/A | 519 | N/A |
| 12/31/2017 | 1,725 | 418 | N/A | 474 | N/A |
| 9/30/2017 | 1,670 | 509 | N/A | 723 | N/A |
| 6/30/2017 | 1,632 | 395 | N/A | 694 | N/A |
| 3/31/2017 | 1,600 | 657 | N/A | 749 | N/A |
| 12/31/2016 | 1,599 | 714 | N/A | 644 | N/A |
| 9/30/2016 | 1,595 | 708 | N/A | 506 | N/A |
| 6/30/2016 | 1,573 | 1,011 | N/A | 484 | N/A |
| 3/31/2016 | 1,507 | 904 | N/A | 400 | N/A |
| 12/31/2015 | 1,466 | 652 | N/A | 383 | N/A |
| 9/30/2015 | 1,407 | 663 | N/A | 448 | N/A |
| 6/30/2015 | 1,351 | 173 | N/A | 449 | N/A |
| 3/31/2015 | 1,327 | 186 | N/A | 354 | N/A |
| 12/31/2014 | 1,289 | 340 | N/A | 355 | N/A |
| 9/30/2014 | 1,231 | 194 | N/A | 369 | N/A |
| 6/30/2014 | 1,203 | 282 | N/A | 300 | N/A |
| 3/31/2014 | 1,161 | 250 | N/A | 438 | N/A |
| 12/31/2013 | 1,117 | 175 | N/A | 425 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UTHR's forecast earnings growth (6.8% per year) is above the savings rate (2.5%).
Earnings vs Market: UTHR's earnings (6.8% per year) are forecast to grow slower than the US market (15.2% per year).
High Growth Earnings: UTHR's earnings are forecast to grow, but not significantly.
Revenue vs Market: UTHR's revenue (6.7% per year) is forecast to grow slower than the US market (8.8% per year).
High Growth Revenue: UTHR's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UTHR's Return on Equity is forecast to be low in 3 years time (12.3%).